ARIA News 5.87 07/15/2014 04:35:51 Ariad Pharmaceuticals (AR

New Post Public Reply Private Reply Replies (0) Message Board

Jul 15, 2014 at 5:35 AM

Ariad Pharmaceuticals (ARIA) 5.87 $ARIA

ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe
Business Wire - Mon Jul 14, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited additional information regarding Iclusig(R) (ponatinib) as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD's response and input from the agency's Scientific Advisory Group, the Company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use (CHMP) at its meeting in October 2014.

ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today
at The Street - Tue Jul 08, 9:39AM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.

OncoGenex's Apatorsen in Phase II for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 3:30PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen is in phase II study (Cedar) for advanced squamous cell lung cancer.

Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:42AM CDT
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock

Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.

Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:51AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.

Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.

Ariad Pharmaceuticals Up 75.1% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Wed Jul 02, 9:35AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on November 22nd, 2013 at $3.67. In approximately 7 months, Ariad Pharmaceuticals has returned 75.07% as of today's recent price of $6.43.

Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:46AM CDT
Tesaro (TSRO) was a big mover last session, with shares rising nearly 9% on the day.

Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:59AM CDT
Karyopharm Therapeutics stock fell 5.2% last trading session, reversing its recent trend

Salix Pharmaceuticals (SLXP) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:51AM CDT
Salix Pharmaceuticals Ltd. (SLXP) was a big mover last session, as its shares rose over 11% on the day.

IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.

Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 7:59AM CDT
Auxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month

UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.

Pacira's Exparel Positive in Phase IV Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:30AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) announced significant results from a series of phase IV studies on Exparel.

QLT Inc. (QLTI) in Focus: Stock Surges 14.63% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 7:44AM CDT
QLT Inc. (QLTI) was a big mover last session, as the company saw its shares rally nearly 15% on the day.

Clinical Studies, Trials Results, Appointments, and Technical Updates - Analyst Notes on Ohr, Ariad, Arrowhead, CytRx and Karyopharm Therapeutics
PR Newswire - Fri Jun 27, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Arrowhead Research Corp. (NASDAQ: ARWR), CytRx Corporation (NASDAQ: CYTR) and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4203-100free.

Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:51AM CDT
Heron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.

Stock Watchout on Biotech Industry -- Research on ARIAD Pharma, Geron, Seattle Genetics, and Sarepta Therapeutics
PR Newswire - Thu Jun 26, 6:30AM CDT
On Wednesday, June 25, 2014, the NASDAQ Composite ended at 4,379.76, up 0.68%, the Dow Jones Industrial Average advanced 0.29%, to finish the day at 16,867.51, and the S&P 500 closed at 1,959.53, up 0.49%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 708.15, up 1.08%, and the index has advanced 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corp. (NASDAQ: GERN), Seattle Genetics Inc. (NASDAQ: SGEN) and Sarepta Therapeutics Inc. (NASDAQ: SRPT). Free technical research on ARIA, GERN, SGEN and SRPT can be downloaded upon signing up at:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Skiptown Expands in Georgia Amid Growing Demand

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Maven Pet's AI Paw-tnership: Changing Pet Care Landscape

AI in the World of Doggie Docs In today's tech-driven world, pet owners are turning to artificial intelligence like never before. Forget flipping through outdated dog-care books—nearly half of us are drilling ChatGPT for health tips on our four-legged pals. Yes, it seems we’re asking an AI about Rover's health more than some other major life decisions. But let's face...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...